arrow
M

Martha Grogan

department of cardiovascular diseases
H指数:65
被引数:2.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Subtype specific artificial intelligence modelling of cardiac amyloidosis using echocardiography and electrocardiography

利用超声心动图和心电图进行心脏淀粉样变性亚型特异性人工智能建模

2026-08-280
OA
Cardiovascular-Related Mortality and Hospitalizations in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: A Post Hoc Analysis of the Phase 3 ATTR-ACT and Long-Term Extension

使用Tafamidis治疗的转甲状腺素蛋白淀粉样变性心肌病患者的心血管相关死亡率和住院率:ATTR-ACT III期试验及其长期扩展研究的事后分析

2026-08-270
OAAI
Clonal plasma cell features in light chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response
2025-11-011
OAAI
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy

阿卡拉米定对转甲状腺素蛋白淀粉样变性心肌病全因死亡率和心血管住院的疗效

2025-03-011
OAAI
Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage

心脏ATTR和AL的全组织蛋白质组学分析揭示了组织损伤的机制

2025-01-080
PRE
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
2025-01-0213
PRE
Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design (vol 35, pg 3604, 2021)

Nt-probnp非常高的新诊断AL淀粉样变性患者的结局: 对试验设计的影响 (第35卷,3604页,2021)

LEUKEMIA
IF13.4
2024-06-170
OAAI